Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signature

The use of primary mesenchymal stem cells (间充质干细胞) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (诱导多能干细胞) -derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these ageing-associated drawbacks. The importance of this concept is manifested by the successful Phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service- 英国; a Phase 2 trial is planned for 2019. 笔记, this trial is independent of the work carried out by Spitzhorn et al.-described below.